Pharmacological targeting of the FGFR-KLB system dramatically improves metabolic disturbances in rodent models of obesity, T2D, and NAFLD, observations that paved the way for more advanced drug development. The gene discussed is KLB; the disease is type 2 diabetes mellitus.